522 related articles for article (PubMed ID: 31943590)
1. Epidemiology and risk factors associated with Pneumocystis jirovecii pneumonia in kidney transplant recipients after 6-month trimethoprim-sulfamethoxazole prophylaxis: A case-control study.
Park SY; Jung JH; Kwon H; Shin S; Kim YH; Chong YP; Lee SO; Choi SH; Kim YS; Woo JH; Kim SH; Han DJ
Transpl Infect Dis; 2020 Apr; 22(2):e13245. PubMed ID: 31943590
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation.
Prasad GVR; Beckley J; Mathur M; Gunasekaran M; Nash MM; Rapi L; Huang M; Zaltzman JS
BMC Infect Dis; 2019 Apr; 19(1):311. PubMed ID: 30953458
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients and appraisal of strategies for selective use of chemoprophylaxis.
de Boer MG; Kroon FP; le Cessie S; de Fijter JW; van Dissel JT
Transpl Infect Dis; 2011 Dec; 13(6):559-69. PubMed ID: 21689251
[TBL] [Abstract][Full Text] [Related]
4. Pneumocystis pneumonia in solid organ transplant recipients: not yet an infection of the past.
Wang EH; Partovi N; Levy RD; Shapiro RJ; Yoshida EM; Greanya ED
Transpl Infect Dis; 2012 Oct; 14(5):519-25. PubMed ID: 22571389
[TBL] [Abstract][Full Text] [Related]
5. Pneumocystis jirovecii pneumonia in renal transplant recipients: a national center experience.
Borstnar S; Lindic J; Tomazic J; Kandus A; Pikelj A; Prah J; Skvarc M; Godnov U; Kovac D
Transplant Proc; 2013 May; 45(4):1614-7. PubMed ID: 23726632
[TBL] [Abstract][Full Text] [Related]
6. Tolerability of low-dose sulfamethoxazole/trimethoprim for Pneumocystis jirovecii pneumonia prophylaxis in kidney transplant recipients.
Zmarlicka M; Martin ST; Cardwell SM; Nailor MD
Prog Transplant; 2015 Sep; 25(3):210-6. PubMed ID: 26308779
[TBL] [Abstract][Full Text] [Related]
7. Impact of Increased Duration of Trimethoprim-Sulfamethoxazole Prophylaxis for Pneumocystis Pneumonia After Renal Transplant.
Chapman FA; Dickerson JE; Daly C; Clancy M; Geddes C
Ann Transplant; 2019 Dec; 24():625-630. PubMed ID: 31806862
[TBL] [Abstract][Full Text] [Related]
8. Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.
Kitazawa T; Seo K; Yoshino Y; Asako K; Kikuchi H; Kono H; Ota Y
J Infect Chemother; 2019 May; 25(5):351-354. PubMed ID: 30711257
[TBL] [Abstract][Full Text] [Related]
9. Switch to atovaquone and subsequent re-challenge with trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis in a kidney transplant population.
McLaughlin MM; Galal A; Richardson CL; Sutton SH; Barr VO; Patel N; Mitchell P; Stosor V
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28833985
[TBL] [Abstract][Full Text] [Related]
10. Successful prophylaxis against Pneumocystis carinii pneumonia in HIV-infected children using smaller than recommended dosages of trimethoprim-sulfamethoxazole.
Fisher RG; Nageswaran S; Valentine ME; McKinney RE
AIDS Patient Care STDS; 2001 May; 15(5):263-9. PubMed ID: 11530767
[TBL] [Abstract][Full Text] [Related]
11. Pneumocystis jirovecii pneumonia in kidney transplantation.
Goto N; Oka S
Transpl Infect Dis; 2011 Dec; 13(6):551-8. PubMed ID: 22093172
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy evaluation of low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis pneumonia in HIV uninfected patients undergoing hemodialysis: a retrospective observational study.
Yamashita K; Shimomura Y; Ikesue H; Muroi N; Yoshimoto A; Hashida T
BMC Infect Dis; 2021 Jul; 21(1):664. PubMed ID: 34238239
[TBL] [Abstract][Full Text] [Related]
13. Pneumocystis jirovecii pneumonia is rare in renal transplant recipients receiving only one month of prophylaxis.
Anand S; Samaniego M; Kaul DR
Transpl Infect Dis; 2011 Dec; 13(6):570-4. PubMed ID: 22093215
[TBL] [Abstract][Full Text] [Related]
14. Higher risk of urinary tract infections in renal transplant recipients receiving pentamidine versus trimethoprim-sulfamethoxazole (TMP-SMX) for Pneumocystis pneumonia prophylaxis.
Fu W; Barahona M; Harkness T; Cohen E; Reardon D; Yoo PS
Clin Transplant; 2020 Nov; 34(11):e14067. PubMed ID: 32810885
[TBL] [Abstract][Full Text] [Related]
15. Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids-clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole.
Park JW; Curtis JR; Kim MJ; Lee H; Song YW; Lee EB
Arthritis Res Ther; 2019 Sep; 21(1):207. PubMed ID: 31521185
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic effect of low-dose trimethoprim-sulfamethoxazole for Pneumocystis jirovecii pneumonia in adult recipients of kidney transplantation: a real-world data study.
Chen RY; Li DW; Wang JY; Zhuang SY; Wu HY; Wu JJ; Qu JW; Sun N; Zhong C; Zhu C; Zhang M; Yu YT; Yuan XD
Int J Infect Dis; 2022 Dec; 125():209-215. PubMed ID: 36243280
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety evaluation of thrice weekly double strength vs daily single strength trimethoprim-sulfamethoxazole for prophylaxis of pneumocystis jirovecii pneumonia after kidney transplantation: a two year prospective cohort study.
Yang H; Pang L; Hu X; Wang W; Xu B; Zhang X; Liu L
J Pharm Pharm Sci; 2021; 24():220-226. PubMed ID: 33956598
[TBL] [Abstract][Full Text] [Related]
18. The risk factor analysis and treatment experience in pneumocystis jirovecii pneumonia after kidney transplantation.
Yang P; Zhu X; Liang W; Cai R
Mycoses; 2021 May; 64(5):495-502. PubMed ID: 33368732
[TBL] [Abstract][Full Text] [Related]
19. The impact of trimethoprim-sulfamethoxazole as Pneumocystis jiroveci pneumonia prophylaxis on the occurrence of asymptomatic bacteriuria and urinary tract infections among renal allograft recipients: a retrospective before-after study.
Singh R; Bemelman FJ; Hodiamont CJ; Idu MM; Ten Berge IJ; Geerlings SE
BMC Infect Dis; 2016 Feb; 16():90. PubMed ID: 26912326
[TBL] [Abstract][Full Text] [Related]
20. Dapsone safety in hematology patients: Pathways to optimizing Pneumocystis jirovecii pneumonia prophylaxis in hematology malignancy and transplant recipients.
Urbancic KF; Pisasale D; Wight J; Trubiano JA
Transpl Infect Dis; 2018 Dec; 20(6):e12968. PubMed ID: 30030892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
